CymaBay Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
7575 Gateway Boulevard, Suite 110, Newark, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
METABOLEX, INC. (to 11/10/2009), METABOLEX INC (to 3/5/2009)
Latest financial report
10-K - Q4 2023 - Feb 28, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.09K % -8.42%
Debt-to-equity 63.4 % -53.9%
Return On Assets -31 % +50.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115M shares
Common Stock, Shares, Outstanding 114M shares +34.5%
Entity Public Float 955M USD +338%
Common Stock, Value, Issued 11K USD +37.5%
Weighted Average Number of Shares Outstanding, Basic 106M shares +21%
Weighted Average Number of Shares Outstanding, Diluted 106M shares +21%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 80.8M USD +18.8%
General and Administrative Expense 52M USD +107%
Operating Income (Loss) -102M USD -9.2%
Nonoperating Income (Expense) -3.69M USD +71.4%
Net Income (Loss) Attributable to Parent -105M USD +0.6%
Earnings Per Share, Basic -0.99 USD/shares +18.2%
Earnings Per Share, Diluted -0.99 USD/shares +18.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 207M USD +918%
Cash, Cash Equivalents, and Short-term Investments 416M USD +207%
Assets, Current 404M USD +192%
Property, Plant and Equipment, Net 465K USD -33.7%
Operating Lease, Right-of-Use Asset 4.8M USD +2741%
Other Assets, Noncurrent 3.23M USD +10.9%
Assets 435M USD +206%
Accounts Payable, Current 3.83M USD +249%
Employee-related Liabilities, Current 8.98M USD +55.4%
Liabilities, Current 36.8M USD +139%
Operating Lease, Liability, Noncurrent 4.85M USD +16060%
Liabilities 142M USD +34.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 144K USD
Retained Earnings (Accumulated Deficit) -978M USD -12.1%
Stockholders' Equity Attributable to Parent 292M USD +708%
Liabilities and Equity 435M USD +206%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 6.43M USD
Net Cash Provided by (Used in) Financing Activities 93.1M USD +279%
Net Cash Provided by (Used in) Investing Activities -60.6M USD -18.9%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 114M shares +34.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 207M USD +920%
Deferred Tax Assets, Valuation Allowance 170M USD +17.2%
Deferred Tax Assets, Gross 171M USD +17.8%
Operating Lease, Liability 4.86M USD +600%
Payments to Acquire Property, Plant, and Equipment 195K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -105M USD +1.33%
Lessee, Operating Lease, Liability, to be Paid 8.36M USD +1035%
Property, Plant and Equipment, Gross 3.9M USD +12.9%
Operating Lease, Liability, Current 7K USD -98.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 527K USD +1657%
Lessee, Operating Lease, Liability, to be Paid, Year One 30K USD -95.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.51M USD +8060%
Lessee, Operating Lease, Liability, to be Paid, Year Three 867K USD
Deferred Tax Assets, Operating Loss Carryforwards 91.8M USD +4.68%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 10M USD +33.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 894K USD
Operating Lease, Payments 176K USD +2.92%
Additional Paid in Capital 1.27B USD +39.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 199K USD +17.8%
Share-based Payment Arrangement, Expense 15.2M USD +60%
Interest Expense 18.9M USD +27.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%